北美与欧洲甲基氯异噻唑啉酮/甲基异噻唑啉酮接触过敏患病率趋势
该回顾性分析比较2009至2018年北美与欧洲斑贴试验对MCI/MI及MI的阳性率。欧洲MCI/MI阳性率在2013至2014年达峰后下降,北美则持续上升;结果提示欧洲异噻唑啉酮过敏减少而北美继续增加,可能与欧洲更早且更严格的MI监管有关。
要点
- 2009至2018年北美与欧洲共226161人对MCI/MI、118779人对MI接受斑贴试验。
- 欧洲MCI/MI阳性率2013至2014年达峰后下降,2017至2018年ESSCA为4.4%、IVDK为3.2%。
- 北美MCI/MI阳性率持续上升,2017至2018年达10.8%,MI阳性率为15.0%。
核心结论
- 研究结果提示,与北美持续增加相反,欧洲异噻唑啉酮过敏正在减少。
- 这一趋势可能与欧洲对MI更早且更严格的政府监管相吻合。
研究设计与样本
- 回顾性分析北美接触性皮炎组、欧洲接触性过敏监测系统(ESSCA)和皮肤科信息网络(IVDK)数据库。
- 纳入2009至2018年在北美和欧洲转诊斑贴试验诊所就诊并接受斑贴试验的患者。
- 参与中心对226161人进行MCI/MI斑贴试验,对118779人进行MI斑贴试验。
主要发现
- 欧洲MCI/MI阳性率在2013至2014年达峰,ESSCA为7.6%、IVDK为5.4%,2017至2018年降至ESSCA 4.4%、IVDK 3.2%。
- 2017至2018年欧洲MI阳性率ESSCA为5.5%、IVDK为3.4%。
- 北美MCI/MI阳性率在研究期间持续上升,2017至2018年达10.8%。
- 2017至2018年北美MI阳性率为15.0%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The common use of isothiazolinones as preservatives is a global cause of allergic contact dermatitis. Differences in allowable concentrations of methylisothiazolinone (MI) exist in Europe, Canada, and the US. OBJECTIVE: To compare the prevalence of positive patch test reactions to the methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) combination and MI alone in North America and Europe from 2009 to 2018. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis of North American Contact Dermatitis Group, European Surveillance System on Contact Allergies (ESSCA), and the Information Network of Departments of Dermatology (IVDK) databases included data from patients presenting for patch testing at referral patch test clinics in North America and Europe. EXPOSURES: Patch tests to MCI/MI and MI. MAIN OUTCOMES AND MEASURES: Prevalence of allergic contact dermatitis to MCI/MI and MI. RESULTS: From 2009 to 2018, participating sites in North America and Europe patch tested a total of 226 161 individuals to MCI/MI and 118 779 to MI. In Europe, positivity to MCI/MI peaked during 2013 and 2014 at 7.6% (ESSCA) and 5.4% (IVDK) before decreasing to 4.4% (ESSCA) and 3.2% (IVDK) during 2017 and 2018. Positive reactions to MI were 5.5% (ESSCA) and 3.4% (IVDK) during 2017 and 2018. In North America, the frequency of positivity to MCI/MI increased steadily through the study period, reaching 10.8% for MCI/MI during 2017 and 2018. Positive reactions to MI were 15.0% during 2017 and 2018. CONCLUSIONS AND RELEVANCE: The study results suggest that in contrast to the continued increase in North America, isothiazolinone allergy is decreasing in Europe. This trend may coincide with earlier and more stringent government regulation of MI in Europe.
引用
- Reeder MJ, Warshaw E, Aravamuthan S, et al. Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe. JAMA Dermatol. 2023. PMID: 36652228. doi:10.1001/jamadermatol.2022.5991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。